Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

INTRODUCTION:<br>Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/o...

Full description

Bibliographic Details
Main Authors:	Lim, E, Darlison, L, Edwards, J, Elliott, D, Fennell, DA, Popat, S, Rintoul, RC, Waller, D, Ali, C, Bille, A, Fuller, L, Ionescu, A, Keni, M, Kirk, A, Koh, P, Lau, K, Mansy, T, Maskell, NA, Milton, R, Muthukumar, D, Pope, T, Roy, A, Shah, R, Shamash, J, Tasigiannopoulos, Z, Taylor, P, Treece, S, Ashton, K, Harris, R, Joyce, K, Warnes, B, Mills, N, Stokes, EA, Rogers, C, MARS 2 Trialists
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2020

Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

Similar Items